Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRE-ISPY Platform Trial in Solid Tumors
NCT05868226Phase 2Recruiting
- Sponsor
- Quantum Leap Healthcare Collaborative
- Start
- Feb 2023
- Primary completion
- Dec 2030
- Modality
- Bispecific Antibodies, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of evorpacept, zanidatamab and TTX-MC138 in solid tumor, breast cancer and colorectal cancer (CRC) (3 arms), sponsored by Quantum Leap Healthcare Collaborative. Primary endpoints: Incidence of Adverse Events, Incidence of Dose Limiting Toxicities and 4 more. Started Feb 2023; status: recruiting.
02
Drugs
evorpaceptzanidatamabTTX-MC138
03
Conditions
solid tumorbreast cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05868226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05868226.